Global clinical grant spending in 2008, the last year for which complete data are available, reached a new high at $11.5 billion. According to TTC-llc, the breakdown by phase ranged from $0.8 billion for phase I studies, $2.2 billion for phase II studies, and $7.2 billion for phase III studies. Phase IV spending totaled $1.3 billion. The data come from the industry’s largest current database on pharmaceutical clinical grants, GrantPlan®, supplemented with additional data from ClinicalTrials.gov.
Clinical grant spending varied substantially by therapeutic area. The five largest therapeutic areas in phase 1-3 were: Oncology, 23%; Central Nervous System and Mental Disorders, 22%, Cardiovascular diseases, 18%, Endocrine, 10%, Infectious diseases, 7%. Relative phase IV spending differed by therapeutic area, with the five largest being: Central Nervous System and Mental Disorder, 40%; Cardiovascular, 20%; Endocrine, 10%, Infectious Diseases, 7%, and Genitourinary Systems, 4%. Oncology grant spending represented only 3% of phase 4 spending.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.